Silicon Investor (SI) -- The First Internet Community

STOCKTALK

We've detected that you're using an ad content blocking browser plug-in or feature. Ads provide a critical source of revenue to the continued operation of Silicon Investor. We ask that you disable ad blocking while on Silicon Investor in the best interests of our community. If you are not using an ad blocker but are still receiving this message, make sure your browser's tracking protection is set to the 'standard' level.

Revision History For: Accentia Biopharmaceuticals, Inc

01 Jan 2008 04:25 PM <--

Return to Accentia Biopharmaceuticals, Inc

Yahoo post

It looks like the move has started (earlier than I expected). There are some very strong catalysts going into spring 2008 that could give this some legs:

1. The unblinding of the SinuNase Phase III data.

2. The unblinding of the BiovaxID Phase III data.

3. Pending good results for SinuNase, the announcement of a big pharma partnership.

4. Pending good results for SinuNase, the filing for accelerated FDA approval.

5. Pending good results for BiovaxID, the filing for conditional FDA approval.

6. The start of the Revimmune Phase III trial.

7. The announcement of a partner for the Revimmune trial.

messages.finance.yahoo.com